GlassScriptPhysician profile
Michael F Lurakis
NPI 1437228178
$8,507.35
in general payments reported to CMS, 2019-2025
47 companies · $929 in 2025
The $929 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,571 · 2020: $1,619 · 2021: $1,738 · 2022: $1,014 · 2023: $410 · 2024: $1,226 · 2025: $929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,565.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,564.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $854.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $744.31 | 2019-2025 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $719.98 | 2019-2022 | |
| Lilly USA, LLC | $677.69 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $586.82 | 2019-2024 | Breztri, Farxiga |
| Corcept Therapeutics | $560.57 | 2022-2025 | Korlym |
| Amarin Pharma, INC. | $545.86 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $536.00 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $478.47 | 2019-2025 | Jardiance |
| Abbvie INC. | $346.51 | 2020-2024 | |
| Pfizer INC. | $319.48 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $193.70 | 2019-2025 | Zoryve, Livalo |
| Opko Pharmaceuticals, LLC | $162.37 | 2020-2021 | |
| Abbott Laboratories | $153.13 | 2021-2025 | Freestyle Libre 3 |
| Allergan, INC. | $144.88 | 2020 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lurakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.